Published in Int J Clin Pract on March 16, 2007
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax (2010) 2.86
Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir J (2012) 1.96
Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ (2014) 1.67
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2010) 1.58
Retracted Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn Schmiedebergs Arch Pharmacol (2008) 1.12
Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. BMJ (2007) 1.09
Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India (2015) 1.07
A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract (2009) 0.96
Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.92
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res (2011) 0.91
Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy (2009) 0.89
Long-acting beta(2)-agonist and inhaled corticosteroid combination therapy for adult persistent asthma: systematic review of clinical outcomes and economic evaluation. CADTH Technol Overv (2010) 0.86
Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev (2009) 0.85
Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response. Respir Res (2012) 0.82
New approaches to managing asthma: a US perspective. Ther Clin Risk Manag (2008) 0.81
A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany. Int J Clin Pract (2008) 0.80
Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. Int J Clin Pharmacol Ther (2015) 0.79
Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: a randomised, double-blind, cross-over study. Respir Res (2010) 0.78
Satisfaction levels and asthma control amongst Malaysian asthmatic patients on budesonide/formoterol maintenance and reliever therapy: experience in a real-life setting. Patient Relat Outcome Meas (2012) 0.76
Using decision support for population tracking of adherence to recommended asthma guidelines. BMJ Open (2014) 0.75
Chinese expert consensus on bronchial asthma control. J Thorac Dis (2014) 0.75
Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokines. Pharmacol Res Perspect (2016) 0.75
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. J Aerosol Med Pulm Drug Deliv (2016) 0.75
Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelines. World Allergy Organ J (2010) 0.75
Section 1. EPR-3 versus GINA 2008 Guidelines - Asthma Control and Step 3 Care: Highlights of the Asthma Summit 2009: Beyond the Guidelines. World Allergy Organ J (2010) 0.75
Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working Group. Can Respir J (2009) 0.75
Change page: Way forward is not obvious at asthma crossroads. BMJ (2007) 0.75
The frequency of, and adherence to, single maintenance and reliever therapy instructions in asthma: a descriptive analysis. NPJ Prim Care Respir Med (2016) 0.75
Real-Life Clinical Use of Symbicort® Maintenance and Reliever Therapy for Asthmatic Patients in Korea. Allergy Asthma Immunol Res (2018) 0.75
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol (1994) 9.50
Development and validation of a questionnaire to measure asthma control. Eur Respir J (1999) 9.35
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis (1987) 6.69
Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev (2003) 5.77
Tables of the number of patients required in clinical trials using the logrank test. Stat Med (1983) 5.34
Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med (2004) 4.37
Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol (2004) 4.17
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med (2004) 3.96
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet (2006) 3.93
Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet (2004) 3.89
Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest (1999) 3.28
Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest (2006) 2.75
Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust (2003) 2.23
Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax (2004) 2.13
Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med (2006) 2.08
Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest (2000) 2.04
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med (1999) 1.96
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J (2005) 1.70
EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med (2006) 1.65
Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med (1999) 1.45
Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest (2003) 1.42
Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin (2004) 1.21
Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos (1998) 1.11
Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med (2000) 1.10
Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Int J Clin Pract (2005) 0.90
Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers. Eur Respir J (2005) 0.90
A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther (2003) 0.89
A single inhaler for asthma? Am J Respir Crit Care Med (2005) 0.88
Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos (2001) 0.84
[German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. Pneumologie (2013) 3.03
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J (2001) 2.77
Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol (2007) 1.99
Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med (2003) 1.97
Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985) (1993) 1.88
Effect of simulated commercial flight on oxygenation in patients with interstitial lung disease and chronic obstructive pulmonary disease. Thorax (2004) 1.85
Nasal CPAP therapy: effects of different CPAP levels on pressure transmission into the trachea and pulmonary oxygen transfer. Acta Anaesthesiol Scand (2002) 1.76
Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin (2004) 1.57
Endotoxin immunity and the development of the systemic inflammatory response syndrome in critically ill children. Intensive Care Med (2006) 1.52
The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy (2005) 1.51
Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am Rev Respir Dis (1991) 1.49
The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J (1994) 1.42
[Combination of asthma and COPD: more frequent as considered to be?]. Pneumologie (2006) 1.40
Comparison of STIR and spin-echo MR imaging at 1.5 T in 90 lesions of the chest, liver, and pelvis. AJR Am J Roentgenol (1989) 1.40
[Guideline-adherent treatment for asthma]. Internist (Berl) (2008) 1.40
Combined lung injury, meningitis and cerebral edema: how permissive can hypercapnia be? Intensive Care Med (1998) 1.39
[beta(2)-Sympathomimetics: risks for asthma therapy? Lessons from the SMART1 Study. A statement from the German Respiratory Tract League]. Dtsch Med Wochenschr (2007) 1.39
Emergency management of children with severe sepsis in the United Kingdom: the results of the Paediatric Intensive Care Society sepsis audit. Arch Dis Child (2009) 1.34
Sonography of gallbladder duplication and differential considerations. AJR Am J Roentgenol (1985) 1.30
Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis (2000) 1.29
Safety and tolerability of omalizumab. Clin Exp Allergy (2009) 1.26
On the numerical accuracy of the boundary element method. IEEE Trans Biomed Eng (1989) 1.25
[Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin]. Pneumologie (2007) 1.23
Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin (2004) 1.21
Effect of internal thoracic artery preparation on blood loss, lung function, and pain. Ann Thorac Surg (1999) 1.18
Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J (2000) 1.17
Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol (1995) 1.16
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J (2001) 1.16
Mast cell-derived tumour necrosis factor is essential for allergic airway disease. Eur Respir J (2007) 1.16
Multicentre study of fetal cardiac time intervals using magnetocardiography. BJOG (2002) 1.14
Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry (2004) 1.13
Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J (2007) 1.13
Malignant peripheral nerve sheath tumours--report of 8 cases and review of the literature. Acta Neurochir (Wien) (2001) 1.13
Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther (2005) 1.12
Spontaneous intracranial haematomas caused by neoplasms. Acta Neurochir (Wien) (2000) 1.12
Cost of nitric oxide is exorbitant. BMJ (2002) 1.10
Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration (2003) 1.10
Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med (2009) 1.09
Volume conduction effects in EEG and MEG. Electroencephalogr Clin Neurophysiol (1998) 1.09
Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet (1991) 1.07
Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J Clin Invest (1991) 1.06
[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]. Pneumologie (2006) 1.05
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol (2001) 1.04
Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J (1998) 1.03
On the magnetic field distribution generated by a dipolar current source situated in a realistically shaped compartment model of the head. Electroencephalogr Clin Neurophysiol (1987) 1.03
Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol (1985) (1993) 1.02
Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol (2000) 1.01
Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta analysis of randomised controlled trials. Int J Clin Pract (2010) 1.00
Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol (1985) (1990) 1.00
Stroke pattern interpretation: the variability of hypertensive versus amyloid angiopathy hemorrhage. Cerebrovasc Dis (2001) 0.98
Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol (1995) 0.98
Glutathione in induced sputum of healthy individuals and patients with asthma. Thorax (2001) 0.97
Measuring asthma control: a comparison of three classification systems. Eur Respir J (2010) 0.96
Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med (1995) 0.96
Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients. Eur J Clin Invest (2001) 0.96
Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur Respir J (2002) 0.95
A fast method to compute the potential in the multisphere model. IEEE Trans Biomed Eng (1993) 0.95
Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med (1999) 0.95
Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy (2014) 0.95
KATP channel activation induces ischemic preconditioning of the endothelium in humans in vivo. Circulation (2004) 0.94
Surgical treatment of septic deep venous thrombosis. Surgery (1995) 0.93
The effects of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci (1994) 0.93
Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. J Heart Lung Transplant (2001) 0.93
Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol (1985) (1999) 0.93
Study of clinical features of amyloid angiopathy hemorrhage and hypertensive intracerebral hemorrhage. J Zhejiang Univ Sci (2004) 0.93
Recommendations for management of equine athletes with cardiovascular abnormalities. J Vet Intern Med (2014) 0.92
Non-invasive diagnosis of tracheobronchomalacia using a modified ventilation radioisotope lung scan. Arch Dis Child (2003) 0.92
The volume conductor may act as a temporal filter on the ECG and EEG. Med Biol Eng Comput (1998) 0.92
Effects of long-term supplementation with whey proteins on plasma glutathione levels of HIV-infected patients. Eur J Nutr (2002) 0.90
[Guidelines for the diagnosis and treatment chronic obstructive bronchitis and pulmonary emphysema issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für pneumologie]. Pneumologie (2002) 0.90
A prospective study of first attacks of inflammatory bowel disease and non-relapsing colitis. Microbiologic findings. Scand J Gastroenterol (1993) 0.89
Effect of different asthma treatments on risk of cold-related exacerbations. Eur Respir J (2011) 0.89
Guideline for the management of chronic asthma in children--2009 update. S Afr Med J (2009) 0.89
Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy (2008) 0.88
The EEG and MEG, using a model of eccentric spheres to describe the head. IEEE Trans Biomed Eng (1987) 0.88
Unusual locations for cavernous hemangiomas: report of two cases and review of the literature. Acta Neurochir (Wien) (2005) 0.88
A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. Clin Exp Allergy (2003) 0.87
Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med (2003) 0.86
Clinical implications of fetal magnetocardiography. Ultrasound Obstet Gynecol (2002) 0.86
Stability of glutathione in induced sputum: impact of freezing. Respiration (2003) 0.86
Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis. J Cyst Fibros (2004) 0.86
Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med (2010) 0.86
c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer (2001) 0.86
Indoor air pollutants stimulate interleukin-8-specific mRNA expression and protein secretion of alveolar macrophages. Lung (1999) 0.85
The effects of prostacyclin on gastric intramucosal pH in patients with septic shock. Intensive Care Med (1995) 0.85
Soot-exposed mononuclear cells increase inflammatory cytokine mRNA expression and protein secretion in cocultured bronchial epithelial cells. Respiration (2000) 0.84
O2 consumption, aerobic glycolysis and tissue phosphagen content during activation of the Na+/K+ pump in rat portal vein. Pflugers Arch (1984) 0.84
Lymphocyte transformation test in a group of foundry workers exposed to beryllium and non-exposed controls. Eur J Respir Dis Suppl (1986) 0.84
Lung cancer in New South Wales: current trends and the influence of age and sex. Med J Aust (2000) 0.84
Tumor necrosis factor-alpha modulates the selective interference of hypnotics and sedatives to suppress N-formyl-methionyl-leucyl-phenylalanine-induced oxidative burst formation in neutrophils. Crit Care Med (1997) 0.84
Clinical outcome after surgery of intracranial unruptured aneurysms: results of a series between 1991 and 2001. Acta Neurochir Suppl (2002) 0.83
Computation of neuromagnetic fields using finite-element method and Biot-Savart law. Med Biol Eng Comput (1996) 0.83
Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients. Eur Respir J (1997) 0.83
Kalanchoe pinnata inhibits mast cell activation and prevents allergic airway disease. Phytomedicine (2011) 0.83
Prevalence of exercise-associated arrhythmias in normal performing dressage horses. Equine Vet J Suppl (2010) 0.83
Recognition of outstanding performance in medical schools with nontraditional grading systems. J Med Educ (1984) 0.83
Jugular venous pooling during lowering of the head affects blood pressure of the anesthetized giraffe. Am J Physiol Regul Integr Comp Physiol (2009) 0.83
The influence of fetoabdominal tissues on fetal ECGs and MCGs. Arch Physiol Biochem (2002) 0.83
Glutathione in spermatozoa and seminal plasma of infertile men. Hum Reprod (1998) 0.82